News & Updates

New drug applications approved by US FDA as of 1-15 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with antibiotics appears to increase the risk of irritable bowel syndrome (IBS) development, particularly following a gastrointestinal (GI) infection, suggests a study.

Respiratory infections in early childhood are a risk factor for atopic dermatitis (AD), and the higher the number of infections, the greater the risk, as shown in a study.

Having a ChatGPT-based counselling tool in a local specialist HIV and sexual health clinic setting has been shown to be feasible and acceptable to both patients and healthcare professionals (HCPs) in a pilot implementation study from Singapore.

In patients with inflammatory arthritis, temporary interruption of biologic or Janus kinase inhibitor (JAKi) therapies during supplemental COVID-19 vaccination does not help improve humoral immunogenicity and even increases flare risk, as shown in the pragmatic COVER trial.

Macrolide resistance mutations (MRMs) were detected in more than 40 percent of Mycoplasma (M.) genitalium infections among individuals aged 14-59 years in the US in 2017-2018, representing approximately 1.4 million macrolide-resistant infections.

In the treatment or non-cirrhotic patients with chronic hepatitis C virus (HCV) infection, an 8-week course of sofosbuvir–velpatasvir combination has similar efficacy to the standard 12-week course, according to the open-label RESOLVE trial.

Children hospitalized with human metapneumovirus (hMPV) infection experience substantial clinical burden, especially infants and those with underlying comorbidities, according to a study.